mProX™ Human CSNK1A1 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Kimberly
Verified Customer
Gary
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 CK1α mRNA and protein expression in MM patients and cell lines.
129 MM patients' (pts') PCs (left panel), 36 PCL patients' PCs (middle panel), and 18 MM cell lines' PCs (right panel) CSNK1A1 mRNA expression levels were compared to those of four healthy control PCs.
Ref: Manni, Sabrina, et al. "Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways." Oncotarget 8.9 (2017): 14604.
Pubmed: 28099937
DOI: 10.18632/oncotarget.14654
Research Highlights
The CSNK1A1-specific inhibitor D4476 also caused embryonic developmental arrest in zygotes treated with it. These findings offer the first proof of CSNK1A1's unique role in the early stages of mouse embryonic development.
Ma, Zengyou, et al. "Knockdown of Csnk1a1 results in preimplantation developmental arrest in mice." Theriogenology 198 (2023): 30-35.
Pubmed:
36542875
DOI:
10.1016/j.theriogenology.2022.12.018
These findings imply that inhibiting inflammatory factors through targeting Csnk1a1 has an anti-tumor effect, offering a novel approach to the treatment of gliomas.
Liu, Guanzheng, et al. "Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma." Journal of Cellular and Molecular Medicine 25.15 (2021): 7395-7406.
Pubmed:
34216174
DOI:
10.1111/jcmm.16767